INmune Bio, Inc. (INMB)
Largest Insider Buys in Sector
INMB Stock Price History Chart
INMB Stock Performance
About INmune Bio, Inc.
INmune Bio, Inc., a clinical-stage immunotherapy company, focuses on developing drugs to reprogram the patient's innate immune system to treat disease. The company develops and commercializes product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. Its development programs include INKmune, which focuses on treating women with relapse refractory ovarian carcinoma and patients with high-risk myelodysplastic syndrome; INB03, an immunotherapy that treats patients with hematologic malignancies and solid tumors; …
Insider Activity of INmune Bio, Inc.
Over the last 12 months, insiders at INmune Bio, Inc. have bought $902,571 and sold $0 worth of INmune Bio, Inc. stock.
On average, over the past 5 years, insiders at INmune Bio, Inc. have bought $272,455 and sold $1.75M worth of stock each year.
Highest buying activity among insiders over the last 12 months: Moss David J (CFO, Treasurer & Secretary) — $503,769. Juda Scott (director) — $282,647. Tesi Raymond Joseph (President and CEO) — $248,040.
The last purchase of 10,000 shares for transaction amount of $52,868 was made by Moss David J (Chief Financial Officer) on 2024‑09‑30.
List of Insider Buy and Sell Transactions, INmune Bio, Inc.
| 2024-09-30 | Chief Financial Officer | 10,000 0.0481% | $5.29 | $52,868 | -1.48% | |||
| 2024-09-12 | President and CEO | 15,380 0.0776% | $6.38 | $98,048 | -16.90% | |||
| 2024-09-12 | Chief Financial Officer | 7,690 0.0388% | $6.38 | $49,024 | -16.90% | |||
| 2024-06-25 | director | 5,000 0.0257% | $7.27 | $36,350 | -14.27% | |||
| 2024-04-19 | President and CEO | 18,028 0.0984% | $8.32 | $149,993 | -13.62% | |||
| 2024-04-19 | Chief Scientific Officer | 14,423 0.0788% | $8.32 | $119,999 | -13.62% | |||
| 2024-04-19 | CFO, Treasurer & Secretary | 18,028 0.0984% | $8.32 | $149,993 | -13.62% | |||
| 2024-04-19 | director | 29,603 0.1617% | $8.32 | $246,297 | -13.62% | |||
| 2023-11-10 | director | 7,000 0.0391% | $6.95 | $48,650 | +46.38% | |||
| 2023-07-12 | Sale | director | 10,000 0.061% | $11.01 | $110,085 | -4.75% | ||
| 2023-03-17 | CFO, Treasurer & Secretary | 2,500 0.0136% | $6.42 | $16,063 | +27.36% | |||
| 2022-05-26 | President and CEO | 6,300 0.0355% | $6.41 | $40,383 | +21.33% | |||
| 2022-05-26 | CFO, Treasurer & Secretary | 7,700 0.0425% | $6.27 | $48,279 | +21.33% | |||
| 2021-11-17 | director | 2,500 0.0147% | $13.55 | $33,875 | -37.24% | |||
| 2021-11-03 | Sale | President and CEO | 3,626 0.0214% | $20.00 | $72,520 | -56.78% | ||
| 2021-11-03 | Sale | Chief Scientific Officer | 701 0.0041% | $20.00 | $14,020 | -56.78% | ||
| 2021-11-03 | Sale | CFO, Treasurer & Secretary | 1,025 0.0061% | $20.00 | $20,500 | -56.78% | ||
| 2021-10-27 | Sale | President and CEO | 6,517 0.0381% | $20.00 | $130,340 | -56.13% | ||
| 2021-10-27 | Sale | Chief Scientific Officer | 2,357 0.0138% | $20.00 | $47,140 | -56.13% | ||
| 2021-10-27 | Sale | CFO, Treasurer & Secretary | 2,079 0.0122% | $20.00 | $41,580 | -56.13% |
Insider Historical Profitability
| Tesi Raymond Joseph | President and CEO | 1554106 7.0092% | $4.77 | 7 | 4 | <0.0001% |
| Lowdell Mark William | Chief Scientific Officer | 1510806 6.8139% | $4.77 | 2 | 4 | <0.0001% |
| Moss David J | Chief Financial Officer | 1285869 5.7994% | $4.77 | 8 | 4 | <0.0001% |
| Juda Scott | director | 71603 0.3229% | $4.77 | 6 | 0 | <0.0001% |
| Powers Linda F | director | 210000 0.9471% | $4.77 | 2 | 1 | <0.0001% |
Institutional Investor Ownership
| The Vanguard Group | $6.36M | 2.74 | 541,329 | 0% | +$0 | <0.0001 | |
| BlackRock | $2.82M | 1.21 | 240,166 | -6.89% | -$208,715.36 | <0.0001 | |
| MAI Capital Management, LLC | $2.13M | 0.92 | 181,410 | +85.09% | +$979,926.73 | 0.02 | |
| RHENMAN & PARTNERS ASSET MANAGEMENT AB | $2.09M | 0.9 | 178,284 | 0% | +$0 | 0.2 | |
| Geode Capital Management | $2.01M | 0.86 | 170,802 | +0.45% | +$8,955.09 | <0.0001 |